[Congressional Record Volume 169, Number 47 (Tuesday, March 14, 2023)]
[Senate]
[Page S756]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]



                                Insulin

  Mr. President, now, on insulin and the CBO, it is another important 
day for millions of Americans who rely on insulin. Following Eli 
Lilly's recent announcement that they are capping insulin costs at $35 
a month, Novo Nordisk announced today that they are following suit, 
slashing prices on some insulin products by as much as 75 percent.
  It is good news that these enormous drug pharmaceutical companies are 
waking up to the injustice of price gouging of Americans who rely on 
insulin daily. There is no justification--none--for having insulin cost 
$300 or $500 or more a month. People who need that insulin for their 
health, for their safety, for their lives can't afford it anymore, and 
this lowering of price is very important.
  As we all know, we Senate Democrats took a major step in righting 
this wrong by capping insulin costs at $35 a month for Americans on 
Medicare. It is my hope that both parties can build on this good work 
with commonsense bipartisan legislation to extend that $35 cap to all 
Americans.
  Lowering insulin costs is a good policy that everyone on both sides 
of the aisle should get behind. This is not a Democratic issue. This is 
not a Republican issue. It is something that affects people in every 
city, in every State and is an American issue.